牛牛AI助理已提取核心訊息
Matthew Richard Moore, SVP and Chief Business Officer of Arcutis Biotherapeutics, acquired a total of 70,398 shares of common stock on February 13, 2024, as per the latest SEC filings. These transactions were classified as 'Grant, award or other acquisition' under transaction code 'A'. Following these acquisitions, Moore's direct holdings in the company increased to 149,488 shares. The transactions occurred on a single day, with multiple grants ranging from 4,166 to 26,666 shares each. The acquisitions reflect a strengthening of Moore's investment in the company, signaling potential confidence in Arcutis Biotherapeutics' future prospects.
Matthew Richard Moore, SVP and Chief Business Officer of Arcutis Biotherapeutics, acquired a total of 70,398 shares of common stock on February 13, 2024, as per the latest SEC filings. These transactions were classified as 'Grant, award or other acquisition' under transaction code 'A'. Following these acquisitions, Moore's direct holdings in the company increased to 149,488 shares. The transactions occurred on a single day, with multiple grants ranging from 4,166 to 26,666 shares each. The acquisitions reflect a strengthening of Moore's investment in the company, signaling potential confidence in Arcutis Biotherapeutics' future prospects.
根據美國證券交易委員會的最新文件，Arcutis Biotherapeutics高級副總裁兼首席商務官馬修·理查德·摩爾於2024年2月13日共收購了70,398股普通股。根據交易代碼 “A”，這些交易被歸類爲 “授予、授予或其他收購”。在這些收購之後，摩爾在該公司的直接持股量增加到149,488股。這些交易在一天內進行，多筆贈款每股從4,166股到26,666股不等。這些收購反映出摩爾對該公司的投資有所加強，這表明人們對Arcutis Biotherapeutics的未來前景可能充滿信心。
根據美國證券交易委員會的最新文件，Arcutis Biotherapeutics高級副總裁兼首席商務官馬修·理查德·摩爾於2024年2月13日共收購了70,398股普通股。根據交易代碼 “A”，這些交易被歸類爲 “授予、授予或其他收購”。在這些收購之後，摩爾在該公司的直接持股量增加到149,488股。這些交易在一天內進行，多筆贈款每股從4,166股到26,666股不等。這些收購反映出摩爾對該公司的投資有所加強，這表明人們對Arcutis Biotherapeutics的未來前景可能充滿信心。
有用
沒用